We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ultraviolet Light Therapy for Systemic Lupus Erythematosus

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2004 by National Center for Research Resources (NCRR).
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00004375
First Posted: October 19, 1999
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Louisiana State University Health Sciences Center in New Orleans
Information provided by:
National Center for Research Resources (NCRR)
October 18, 1999
October 19, 1999
December 9, 2005
September 1991
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Ultraviolet Light Therapy for Systemic Lupus Erythematosus
Not Provided

OBJECTIVES:

I. Evaluate the mechanisms of ultraviolet A-1 light therapy in patients with systemic lupus erythematosus and normal controls.

PROTOCOL OUTLINE:

Treatment with ultraviolet A-1 light is administered 5 days a week for 6 weeks, at the lowest dose or frequency required to maintain a response. The dose and frequency are progressively decreased over the next 9 weeks.

Interventional
Phase 2
Primary Purpose: Treatment
Systemic Lupus Erythematosus
Procedure: ultraviolet A-1 light treatment
Not Provided
McGrath H, Martínez-Osuna P, Lee FA. Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus. Lupus. 1996 Aug;5(4):269-74.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
20
Not Provided
Not Provided

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Patients ages 15 to 70 with symptomatic systemic lupus erythematosus meeting American Rheumatism Association criteria and normal controls

--Prior/Concurrent Therapy--

No requirement for tetracycline or other photosensitizing drugs

Sexes Eligible for Study: All
15 Years to 70 Years   (Child, Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00004375
NCRR-M01RR05096-0002
LSUMC-1765
LSUMC-910067
Not Provided
Not Provided
Not Provided
Not Provided
National Center for Research Resources (NCRR)
Louisiana State University Health Sciences Center in New Orleans
Study Chair: Hugh McGrath, Jr. Louisiana State University Health Sciences Center in New Orleans
National Center for Research Resources (NCRR)
January 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP